SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Last trade$31.19
Day change-$1.05 (-3.26%)
Day range$30.15 – $32.72
Volume37,713
Market cap$1.08B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.08B
Price / earnings
—
Price / book
5.13×
Price / sales
—
EV / sales
—
EV / EBITDA
-11.81×
Profitability
Earnings per share
-$2.02
Return on assets
-29.93%
Return on equity
-32.19%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
15.24×
Quick ratio
15.24×
Cash ratio
14.6×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$58.47M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SGP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Revenue
$0
$0
$0
Cost of revenue
$0
$0
$0
Gross profit
$0
$0
$0
Selling, general and administrative
$16.21M
$11.03M
$6.87M
Research and development
$10.03M
$10.94M
$8.54M
Total operating expenses
$26.25M
$21.97M
$15.41M
Operating income
-$26.25M
-$21.97M
-$15.41M
Interest expense
$0
$0
$0
Income before taxes
-$24.25M
-$19.86M
-$13.82M
Income taxes
$0
$0
$0
Net income
-$24.25M
-$19.86M
-$13.82M
Net income attributable to common shareholders
-$24.25M
-$19.86M
-$13.82M
EBITDA
-$25.97M
-$21.63M
-$15.09M
Basic earnings per share
-$0.73
-$0.59
-$0.69
Diluted earnings per share
-$0.73
-$0.59
-$0.69
Recent news
Company coverage with links to the original publishers.
SpyGlass Pharma, a late-stage biopharmaceutical company, announced the appointment of Shannon Treviño as general counsel. Treviño brings extensive legal experience from her previous role as General Counsel at Inari Medical, where she oversaw the company's $4.9 billion acquisition by Stryker. She will support SpyGlass's Phase 3 trials for its BIM-IOL System, a drug delivery device designed to treat glaucoma and ocular hypertension.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Oct 22, 2009
$0.065
Nov 30, 2009
recurring
Aug 5, 2009
$0.065
Aug 31, 2009
recurring
Apr 29, 2009
$0.065
May 26, 2009
recurring
Feb 4, 2009
$0.065
Feb 27, 2009
recurring
Nov 5, 2008
$0.065
Nov 25, 2008
unknown
Stock splits
Historical share-structure events and their execution dates.